These include i) fMRI of emotional stimuli, ii) molecular imaging of the SERT binding, iii) a pharmacological challenge and treatment with an SSRI, iv) SERT genotyping, and v) psychometric scales in both healthy control subjects (HCs) as well as patients with MDD. This evidence concerns the gene SLC6A4 and major depressive disorder.